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Key Messages
• The aim was to identify biomarkers predicting effectiveness of the 5-HT3R antagonist (ramosetron) in IBS-D.
• Colonic mucosal S100A and TPH mRNA expression levels and TPH1 SNPs were analyzed in 42 treated
patients.
• Increased S100A10 and TPH1 expression as well TPH1 high producer SNPs appears to be associated with not
only diarrhea symptoms, but also greater ramosetron effectiveness in IBS-D patients.
• TPH1 gene polymorphisms and S100A10 expression correlating with 5-HT signaling may possibly lead to
prospective identification of ramosetron non-response.
Abstract
Background Serotonin type 3 receptor (5-HT3R) antag-
onists are potentially useful therapeutic agents for
diarrhea-predominant irritable bowel syndrome
(IBS-D). To identify biomarkers predicting effective-
ness of the 5-HT3R antagonist (ramosetron) in IBS-D.
Methods Irritable bowel syndrome-D Japanese sub-
jects received 2.5 or 5 lg of ramosetron once daily for
4 weeks. Colonic mucosal S100A and tryptophan
hydroxylase (TPH) mRNA expression levels were
measured before treatment. Genomic DNA was
extracted from blood and polymorphisms of TPH1
and TPH2 were analyzed. Key Results Forty-two
patients (27 men and 15 women, mean age 42 years)
with IBS-D were included for analysis. Improvement
of IBS symptoms was seen in 26 (61.9%). Baseline
S100A10 (p = 0.02) and TPH1 (p = 0.02) expression
were significantly higher in the ramosetron
responders than in the non-responders. The frequen-
cies of the TPH1 rs4537731G allele in linkage
disequilibrium with the TPH1 rs7130929 T allele
(11.5% vs 50%, p = 0.003; OR: 12; 95% CI: 2.1–69)
along with TPH1 rs211105 C allele (3.8% vs 43.8%,
p = 0.0003; OR: 19; 95% CI: 2.1–181) were signifi-
cantly lower in the responders than in the non-
responders. The mean scores of diarrhea at baseline
were significantly higher (5.2 vs 3.7, p = 0.005) in
patients with TPH1 rs211105 T/T than those with
the G allele. Conclusions & Inferences TPH1 gene
polymorphisms and S100A10 expression, which cor-
relate with 5-HT signaling were associated with
ramosetron effectiveness in IBS-D, and may possibly
lead to prospective identification of the resistance to
treatment.
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INTRODUCTION
Serotonin (5-hydroxytryptamine [5-HT]) is an impor-
tant neurotransmitter and paracrine signaling mole-
cule in both the central nervous system (CNS) and the
gut regulating gastrointestinal (GI) motility, sensation
and secretion.1 5-HT is synthesized by the rate-limit-
ing enzyme tryptophan hydroxylase (TPH) catalyzing
the oxygenation of tryptophan,2,3 which exists as two
isoforms: TPH1 is expressed in the peripheral organs,
especially enterochromaffin (EC) cells in the gut, while
TPH2 is primarily expressed in the CNS and peripheral
serotonergic neurons.4,5 The 5-HT transporter (SERT,
SLC6A4) is thought to play a critical role in the rapid
re-uptake of 5-HT into presynaptic nerve terminals or
epithelial cells of the GI mucosa thereby regulating the
intensity and duration of serotonergic signaling.6–8
However, EC cell counts, 5-HT content, and mRNA
expression of TPH1 and SLC6A4 in the colonic mucosa
of irritable bowel syndrome (IBS) patients have been
reported inconsistently.9,10
Both TPH gene variants have been evaluated inten-
sively in psychiatric or behavioral disorders whose
underlying pathophysiology is related to 5-HT.11–14
The TPH1 promoter variant (11:g.18047335T>C, rs45
37731), intron 3 variant (11:g.18033757T>G, rs211105),
and intron 7 (11:g.18026269G>T, rs1800532) have been
extensively studied with respect to psychiatric disor-
ders.15,16 With respect to IBS, Jun et al.17 previously
reported possible associations between two TPH1 gene
single nucleotide polymorphisms (SNPs), rs4537731
and rs211105, and daily reporting of GI symptoms
including diarrhea, bloating, and loose stools. The
group also tested the correlation between a TPH2 gene
promoter SNP (12:g.71938143G>T, rs4570625) and
stool characteristics in European American women
with IBS. Based on transcriptional regulatory studies in
mice,18 a functional promoter variant was identified
(rs7130929) in the TPH1 promoter in linkage disequi-
librium with the rs4537731 SNP reported by Jun
et al.8,17 The rs7130929 SNP variant forms a bona fide
transcription factor binding site that along with the
rs4537731 SNP generate a functional haplotype.8
5-HT transporter gene-linked polymorphic region (5-
HTTLPR) consists of a 44 base pair (bp) insertion/
deletion into the 50 flanking promoter region of the
gene creating long (l) and short (s) allelic variants,
respectively. The variants of 5-HTTLPR impact the
function of SLC6A4, and the s allele may result in the
decrease of promoter activity reducing reuptake of 5-
HT and thereby increasing 5-HT in the colonic
mucosa.19,20 5-HTTLPR l/s or s/s genotype has been
reported to occur with greater frequency in diarrhea
predominant (IBS-D) than in controls,21 whereas no
association has also been reported.22–24
Recent findings support a role for mucosal 5-HT in
mediating visceral pain and hypersensitivity through 5-
HT3R, and release of 5-HT from the colonic mucosa
that correlates with the severity of abdominal pain/
discomfort in patients with IBS.25 Serotonin type 3
receptor (5-HT3R) antagonists have potential as a
useful therapeutic agent for IBS-D.23,26,27 Ramosetron
hydrochloride (ramosetron), a tetrahydrobenzimidazole
derivative, is one of 5-HT3R antagonists, which has
potential as a useful treatment for patients with IBS-
D.28,29 In a Japanese phase II trial including 418
patients with IBS-D, the monthly responder rate was
significantly higher (43% vs 27%) in the ramosetron
group compared to the placebo group. However, the
significant efficacy of ramosetron compared to placebo
at the final point was confirmed only in men but not in
women, and the placebo effects were stronger and the
incidence of drug-related adverse events was higher in
women compared to men.29 Therefore, ramosetron was
approved only for men in Japan, although alosetron is
indicated only for women with severe, chronic IBS-D
in USA.
There are few studies investigating specific clinical
parameters for predicting the effect of 5-HT3R antag-
onists in patients with IBS-D23,30 and no study for the
ramosetoron. Camilleri et al.23 previously demon-
strated that 5-HTTLPR is associated with colonic
transit response to alosetron in IBS-D patients. How-
ever, subsequent reports concerning the association of
5-HTTLPR with response to 5-HT3R antagonists have
not yet been reported. Moreover, there are no published
data using TPH polymorphisms to predict the effect of
5-HT3R antagonists.
Inflammatory and epithelial cells express S100A8
(also named calgranulin A; myeloid-related protein 8,
MRP8) and S100A9 (calgranulin B; MRP14). These two
myeloid cell proteins can also be induced in epithelial
cells under inflammatory conditions.31,32 S100A8/A9
and calprotectin (the hetero-complex formed by non-
covalent association of S100A8 and S100A9) are
potential markers of gut inflammation and are also
thought to be involved in the IBD pathogenesis.33–36
S100A10 (also known as p11) co-localizes with the 5-
HT1B receptor (5-HT1BR), and S100A10 expression is
reduced in brain tissue of depressed patients but is
increased in rodent brains by antidepressants.37
Stimulation of S100A10 results in relaxation of the
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gastric fundus and a delay stomach emptying.38 The
overexpression of S100A10mRNA levels in the colonic
mucosa of IBS patients has been previously
reported.24,39
We conducted a pilot study to identify genetic
variants that might predict the treatment response to
ramosetron in patients with IBS-D and correlate with
the colonic mucosal expression of 5-HTTLPR and TPH
mRNAs.
METHODS
This was a prospective interventional study of Japanese patients
with IBS-D. The Kawasaki Medical School Ethical Committee
approved the study. Written informed consent was obtained from
each subject. The clinical trial has been register at UMIN Clinical
Trials Registry (UMIN-CTR) as ‘Pathologic and therapeutic
evaluation of IBS and ulcerative colitis (Trial ID:
UMIN000004128)’.
Subjects
Rome III criteria were used to subtype IBS patients as IBS-D. IBS-D
patients were subsequently enrolled, while subjects with other
IBS subtypes were excluded.40 Subjects with a self-reported
organic GI disorder (peptic ulcer disease, inflammatory bowel
disease, malignancy, gallbladder disorder, pancreatitis, or liver
disease), previous surgery of the GI tract were also excluded. All
patients underwent colonoscopy to rule out other organic colon
diseases. All new outpatients with IBS-D who met inclusion
criteria and agreed attendance to the study were enrolled during
the study registration period between February 2010 and January
2013. The enrolled patients received 5 lg of ramosetron once daily
for 4 weeks, and the subjects were allowed to reduce the dose
depending on monitored stool frequency and form to avoid severe
constipation and ischemic colitis. They were prohibited from
changing or adding other medications including antidiarrheal
drugs. Patients taking ramosetron at the first visit and patients
with constipation-predominant (IBS-C), a mixture of both diarrhea
and constipation (IBS-M), and un-subtyped IBS were excluded.
Biopsy samples
Experienced endoscopists performed the colonoscopies. Two
specimens from each sample site, rectum and sigmoid, were
taken using endoscopic forceps (FB240U Olympus, Tokyo, Japan).
The biopsy samples were immediately frozen with liquid nitrogen
and stored at 80 °C until use.
Laser-captured microdissection
The frozen samples obtained at endoscopy were embedded in
optimal cutting temperature (OCT) compound (Sakura Finetek
U.S.A., Inc., Torrance, CA, USA) and cut into serial 8 lm
sections. Before microdissection, up to 8 sections from each block
were mounted on slides and were stained using HistGene laser-
captured microdissection (LCM) Frozen Section Staining Kit
(Arcturus Bioscience, Mountain View, CA, USA). Colonic epithe-
lium was isolated from the cryostat sections using a Leica LMD
7000 (Leica Microsystems, Wetzlar, Germany).
RNA extraction and quantitative polymerase
chain reaction
RNA extraction and Quantitative mRNA analysis of S100A8,
S100A9, A100A10, and TPH1 mRNA expression by reverse
transcriptase-quantitative polymerase chain reaction (RT-qPCR)
was performed as previously reported.18 b-actin was used as an
endogenous reference.
Genotyping
Genomic DNA was extracted from 200 lL of EDTA blood using
FavoPrep Blood Genomic DNA Mini kits (FAVORGEN, Ping-
Tung, Taiwan). To determine the SLC6A4, TPH1 and TPH2
polymorphisms, PCR reactions, PCR-restriction fragment length
polymorphism, or direct sequencing were performed. Based on
previously reported association studies,17,24 we selected 2 SNPs in
SLC6A4, 6 SNPs in the TPH1 gene, and one SNP in the TPH2 gene
for genotyping. The primers and restriction enzymes used to
determine the polymorphisms are shown in Table S1. The samples
for direct sequencing were run on an Applied Biosystems 3130xl
Genetic Analyzer (Applied Biosystems, South San Francisco, CA,
USA) according to the manufacturer’s recommendations.
Patients reported assessment
During the treatment phase, patients recorded their daily IBS
symptoms (severity of abdominal discomfort and/or pain, stool
form, stool frequency, bowel urgency and the feeling of incom-
plete bowel movement) on paper diary cards. The severity of
abdominal discomfort and/or pain was assessed on a 5-point scale
(0: None, 1: Mild, 2: Moderate, 3: Severe, 4: Intolerable) and stool
form was scored on a 7-point ordinal scale according to the Bristol
Stool Form Scale. A responder was defined as a patient who
reported a decrease by one point of scores of abdominal discomfort
and/or pain together with improvement of the score of stool form
in daily IBS symptoms for at least 2 weeks of the 4-week
treatment.29
Questionnaire
Clinical symptoms were also assessed by the GI Symptom Rating
Scale (GSRS) and self-rating depression scale (SDS) before and at
the end of the 4-week ramosetron treatment period. SDS is a 20-
item self-report questionnaire, and the items are scored on a
Likert scale ranging from 1 to 4. The score of patients with
depression ranged between 50 and 69. A score of 70 and above
indicates severe depression.41,42 The severity of GI symptoms was
assessed by the GSRS. The scale depends on how uncomfortable
the symptom has been during the previous week. It is a validated
self-administered questionnaire including 15 questions on a scale
of 1 to 7 and a higher score indicates more discomfort.42,43
Combination scores can assess symptoms of reflux, abdominal
pain, indigestion, diarrhea, and constipation.
Analyses
Values are expressed as the mean  SD or the median with a 25–
75% range, whichever was appropriate depending on whether the
data were normally distributed. Mantel–Haenszel chi-squared
analysis and the unpaired t-test were performed to measure
differences in demographic and clinical characteristics. Statistical
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analyses for significant differences between the two groups were
performed using the unpaired t-test for GSRS and SDS scores and
using the non-parametric Mann–Whitney U-test for mRNA
levels. Differences in genotype frequencies between the two
groups and Hardy–Weinberg equilibrium of allele frequencies at
individual loci were assessed using the Chi-square test or the
Fisher’s exact probability test by comparing the observed and
expected genotype frequencies. The odds ratio (OR) and 95%
confidence interval (CI) were obtained by Mantel–Haenszel chi-
squared analysis and stepwise regression analysis. A two-sided p-
value of less than 0.05 was considered statistically significant. All
statistical computations were performed using SPSS (version 11.0
for Windows; SPSS Inc, Chicago, IL, USA).
RESULTS
A total of 72 patients were candidates for the study.
Thirteen patients with IBS mixed type, five with
constipation-predominant, two with possible UC and
two diagnosed with collagenous colitis did not meet
the inclusion criteria and were excluded. Eight patients
finally refused the study and informed consents were
not obtained. The 42 remaining patients included in
the final analysis (27 men and 15 women, mean age
42 years) were designated as IBS-D by the ROME III
criteria.
The demographic and clinical data are shown in
Table 1. The frequencies of concomitant medicines
were not significantly different between the responder
group and the non-responder group. The overall
response rate was 61.9% (26/42); 59.2% (16/27) for
men and 66.7% (10/15) for women. In the responder
group, 13 patients reduced the dose and one patient
temporarily discontinued the drug due to complete
relief from diarrhea and abdominal pain. Nine respond-
ers reduced the dose due to the adverse events, such as
abdominal discomfort (abdominal distention and upper
abdominal pain) and constipation, and the adverse
events disappeared. IBS symptoms improved after a
reduction in the dose. In the non-responder group,
abdominal discomfort (seven patients), constipation
(one patient) and headache (one patient) were reported.,
one patient reduced the dose, and 10 patients discon-
tinued treatment due to abdominal discomfort (seven
patients), worsened IBS symptoms (two patients), and
headache (one patient). However IBS symptoms in
those patients did not improve. There was no serious
adverse event such as severe constipation or ischemic
colitis in either the responder or non-responder group.
Questionnaire
Baseline scores for diarrhea tended to be higher (5.3 vs
4.5, p = 0.06) in the ramosetron responder group than
in the non-responder group, and the other GSRS scores
and SDS scores were not significantly different
between the two groups (Table 2).
Expression of S100A and TPH1 mRNA at
baseline
Baseline median S100A8 expression levels in the
sigmoid (0.2 9 104 vs 0.5 9 104, p = 0.14) and rectal
(0.3 9 104 vs 0.6 9 104, p = 0.23) mucosa of the
responders tended to be lower than in the non-
responders. However both baseline S100A8 and
S100A9 expression levels in the biopsy samples includ-
ing the LCM samples taken from both the rectum and
sigmoid were not significantly different between the
two groups (Fig. 1A). Median S100A10 expression
levels in the rectal mucosa (13.5 9 102 vs
10.6 9 102, p = 0.07) and the rectal epithelium
(6.0 9 101 vs 3.2 9 101, p = 0.02) of the responders
were higher compared to the non-responders (Fig. 1B),
but not in the sigmoid. However, median TPH1
Table 1 Clinical characteristics of ramosetron responders and non-responders
Total (n = 42) Non-responders (n = 16) Responders (n = 26) p
Age mean (SD) 42 (16) 43 (15) 42 (17) 0.80
Gender men (%) 27 (67.5) 11 (68.8) 16 (61.5) *0.64
Concomitant medicationa 20 8 12 1.0
Calcium Polycarbophil 12 5 7 1.0
Mepenzolate bromide 4 2 2 0.63
Bifidobacterium 3 0 3 0.28
Antidepressant 3 2 1 0.55
Ramosetron dose
5 lg 17 5 12
5–2.5 lg 14 1 13
Discontinuation 11 10 1
Adverse event
Abdominal discomfort 9 7 2
Constipation 8 1 7
Headache 1 1 0
aConcomitant medication for IBS symptoms; p-values, by unpaired t-test or * by chi-squared analyses.
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expression levels in the sigmoid colon of the respond-
ers were significantly higher (3.9 9 103 vs 1.7 9 103,
p = 0.02) compared to the non-responders (Fig. 2), but
not in the rectum nor in the epithelium.
SLC6A4 and TPH genotypes
All 42 subjects were successfully genotyped and the
genotypes and allele frequencies are shown in Table 3.
SLC6A4 genotypes were not significantly different
between the two groups.
As reported by Grasberger et al.8, we also found that
the two proximal promoter TPH1 SNPs at 1066 (11:
g.18047335T>C, rs4537731) and 347(11:
g.18046616C>A, rs7130929) were in complete linkage
disequilibrium. The frequencies of the TPH1
rs4537731 minor C allele (11.5% vs 50%, p = 0.003;
OR: 12; 95% CI: 2.1–69) and TPH1 rs211105 minor G
allele (3.8% vs 43.8%, p = 0.003; OR: 19; 95% CI: 2.1–
181) were significantly lower in the responders than in
the non-responders. Those SNPs were significantly
associated with ramosetron resistance, and the others
including the TPH2 SNP were not associated with
resistance (Table 3). The TPH1 rs211105 minor G
allele was only significantly associated with ramose-
tron resistance (OR: 19; 95% CI: 2.1–181) in the
stepwise regression analysis.
The mean scores of diarrhea at baseline were
significantly higher (5.2 vs 3.7, p = 0.005) in patients
with TPH1 rs211105 T/T than in patients with G
allele. However the scores after treatment were not
significantly different between the two groups. The
other SNPs examined did not influence IBS symptoms
including diarrhea.
DISCUSSION
In this study, we show that ramosetron effectiveness
correlated with TPH1 SNPs and increased TPH1mRNA
levels in the colon. TPH1 rs211105 (11:g.18033757T>G)
Table 2 Comparison of GSRS and SDS scores for ramosetron respond-
ers and non-responders
Non-responder
(n = 16)
Responder
(n = 26) p-values
GSRS scores
Reflux 1.9 (1.0) 2.3 (1.4) 0.31
Abdominal pain 2.3 (1.0) 2.3 (1.0) 0.94
Indigestion 2.4 (1.4) 2.5 (1.2) 0.78
Diarrhea 4.5 (1.4) 5.3 (1.2) 0.06
Constipation 2.4 (1.0) 2.6 (1.0) 0.73
Total score 3.4 (1.0) 3.8 (0.9) 0.28
SDS scores 43 (7) 43 (9) 0.84
p-values: by unpaired t-test.
A
B
Figure 1 Comparisons of baseline relative expressions of S100A 8,
S100 A9, and S100A 10 mRNA between the ramosetron non-
responders group (light bars) and the responders group (dark bars).
Horizontal bar = median; Box = 25th–75th interquartile range;
Vertical lines = range of values. The cycle passing threshold (Ct) was
recorded for each mRNA, and b-actin was used as the endogenous
control for data normalization. p-values were calculated using the non-
parametric Mann–Whitney U-test between the two groups.
Figure 2 Comparisons of baseline relative expressions of TPH 1
mRNA between the ramosetron non-responders group (light bars) and
the responders group (dark bars). Horizontal bar = median;
Box = 25th–75th interquartile range; Vertical lines = range of values.
The cycle passing threshold (Ct) was recorded for each mRNA, and b-
actin was used as the endogenous control for data normalization. p-
values were calculated using the non-parametric Mann–Whitney U-
test between the two groups.
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located within intron 3 and rs4537731 (11:
g.18047335T>C) and rs7130929 (11:g.18046616C>A)
located within the promoter region at 1066 and 347
respectively upstream from the TPH1 transcriptional
start site exhibited the most significant association
with ramosetron efficacy. TPH1 11:g.18047335T>C
(rs4537731) and 11:g.18046616C>A (rs7130929) SNPs
were only 724 base pairs apart and were in complete
linkage disequilibrium with each other, as recently
reported.8 The major alleles (at 1066 T and 347 C on
the sense strand relative to the transcriptional start site)
of the two promoter SNPs (rs4537731 and rs7130929)
both correlated with IBS bowel subtypes and a trend
toward higher TPH1 mRNA levels compared to the
minor C and A alleles, respectively.8,44 Therefore, the
clinical response to ramosetron seems to correlate best
with increased TPH1 expression in the colonic mucosa
and presumably increased 5-HT tissue levels. Our
results are indeed consistent with those reported by
Grasberger et al.8 indicating that the rs7130929 C/C
genotype was more common in IBS-D subjects.
There are no studies reporting the function of the
TPH1 rs211105 intronic SNP and little is known about
the impact of DNA variants in the TPH1 gene. The
mean diarrhea scores were significantly higher in our
patients with the TPH1 rs211105 T/T genotype than
those carrying the minor G allele indicating that the
SNPs might exhibit function and reflect the level of
5-HT biosynthesis. In contrast, Jun et al. investigated
TPH1 SNPs in Caucasian women with mainly the IBS
constipationbowel subtype (IBS-C) and reported that the
severity of diarrhea symptoms associatedwith theTPH1
rs211105G/G or G/T instead of the T/T genotype.
However, they failed to confirm a significant associa-
tion of the individual SNPs with any IBS subtypes.
Camilleri et al.23 previously demonstrated that 5-
HTTLPR genotypes in IBS-D patients were associated
with colonic transit in response to alosetron, a 5-HT3R
antagonist. Specifically, the observed a greater response
in those subjects with the minor 5-HTTLPR l/l genotype
compared to the major s/s or s/l genotypes. However, in
our study, there were no subjects with the l/l genotype.
Therefore we compared the frequency of the s/s and l/s
genotype between the two groups and observed a greater
responsewith the s/s compared to l/s genotype, although
the difference was not significant. The prevalence of the
l/l genotype has been consistently reported to be less
than 6% in Korea and Japan, which is in contrast to the
Far Eastern, Turkish and US studies showing that a
genotype frequency greater than 20%.21,22,24,45 The
TPH1 and 5-HTTLPR polymorphisms differ according
to race. Moreover, the variation in background preva-
lence seems to not only influence the statistical power
but also might confound detection precluding genotype-
related associations.
A recent phase II clinical trial demonstrated the
efficacy of an oral TPH1 inhibitor acting locally on the
GI mucosa in relieving symptoms of non-constipating
IBS. The clinical response to the TPH1 inhibitor corre-
lated with a decrease in urine excretion of a 5-HT
Table 3 Comparison of genotype frequencies between ramosetron responders and non-responders
Allele frequencies
pa for HWE Genotype
Ramosetron
p-valuesNon-responders (n = 16) Responders (n = 26)
SLC6A4
5-HTTLPR
del(s)/ins(l)
l = 0.18, s = 0.82
p = 0.38
ll/ls/ss
ss (%)
0/8/8
50
0/7/19
73.1
0.13
SLC6A4 intron 2
VNTR
10rep=0.12
12rep=0.88
p = 0.69
10/12 & 12/12rep 2/14 8/18 0.27
TPH1 rs4537731
1066 T > C
T = 0.87, C = 0.13
p = 0.93
TT/TC/CC
C allele %
8/7/1
50
24/2/0
11.5
0.003
TPH1 rs7130929
347 C > A
C = 0.87, A = 0.13
p = 0.93
CC/CA/AA
A allele %
8/7/1
50
24/2/0
11.5
0.003
TPH1 rs684302
7465 C > T
C = 0.42, T = 0.68
p = 0.34
CC/CT/TT
C allele %
2/7/7
56.2
3/10/13
50
0.69
TPH1 rs211105
12 517 T > G
T = 0.89, G = 0.11
p = 0.58
TT/GT/GG
G allele %
9/6/1
43.8
25/1/0
3.8
0.003
TPH1 rs1800532
218 G>T
G = 0.33, T = 0.67
p = 0.66
GG/GT/TT
T allele %
3/6/7
56.2
13/10/3
50
0.69
TPH1 rs1799913
779 G > T
G = 0.32, T = 0.68
p = 0.90
GG/GT/TT
G allele %
2/7/7
56.2
13/10/3
50
0.69
TPH2 rs4570625
709 G > T
G = 0.49, T = 0.51
p = 0.18
GG/GT/TT
G allele %
3/11/2
87.5
4/16/6
76.9
0.69
p-values by the chi-squared test; aHardy–Weinberg equilibrium (HWE) of allele frequencies at individual loci was assessed by comparing the observed
and expected genotype frequencies.
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metabolite reflecting reduced 5-HT biosynthesis.46–48
Therefore, inhibiting the TPH1 enzyme seems to
improve IBS-D symptoms by reducing 5-HT biosynthe-
sis. The TPH1 SNPs correlating with enhanced TPH1
expression perhaps increase 5-HT in the colonicmucosa
which ostensibly could worsen IBS-D symptoms.4,5,8,44
Baseline diarrhea scores tended tobehigher (more severe
symptoms) in our responders than in the non-respond-
ers. Ramosetron seemed to be more effective for the
patients with severe symptoms, especially diarrhea and
probably abdominal pain.On the other hand, there is the
possibility that specific TPH1 genotypes might be
important in identifying patients whose IBS-D is truly
related to abnormal serotonergic function rather than to
other causative mechanisms such as food tolerance or
bile acid malabsorption.49–51 Additional studies that
correlate TPH1 genotypes, a specific dose of ramosetron
and symptom response are desirable to implement
functional genomics assessments for IBS.
To our knowledge, this study is the first study to
demonstrate a significant association of decreased
S100A10 rectal expression in patients with IBS-D with
ramosetron ineffectiveness. S100A10 expression levels
in the rectal epithelium isolated by LCM were signifi-
cantly higher in the responders than in the non-
responders, but not in the rectal biopsy samples. In a
recent study, S100A10 expression in the rectal epithe-
lium of patients with IBS-D was significantly higher
than in controls, but not mucosal expression.24 This
result may be due to the fact that epithelial cells express
S100A10 and biopsy samples taken from the patients
with IBS-D contains small amount of inflammatory
cells and other stromal cells. In fact relative S100A10 /b-
actin mRNA expression in the rectal epithelium were
higher in the LCM samples compared to the biopsy
samples. S100A10 was recently reported to induce 5-
HT4 receptor (5-HT4R) surface expression thereby facil-
itating 5-HT4R signaling, as well 5-HT1BR.
39,52 In our
recent study, colonic mucosal S100A10 expression in
the rectal mucosa was significantly higher in the IBS-D
patients than in controls or UC patients.24 It is still
unclear whether 5-HT4R or 5-HT1BR signaling plays
some role in determining the effectiveness of ramose-
tron. Further investigation of histological inflammation
and expression of inflammatory cytokines in colonic
tissue is required, and investigation of S100A expression
levels in response to ramosetron is also required.
In a previous Japanese clinical trial, 163 of 270 (60.4%)
IBS-D patients taking 5 lg ramosetron reported adverse
events. GI disorders such as hard stool, constipation,
abdominal distension, and upper abdominal pain were
the most frequently reported adverse events, which
occurred in 25.9% of participants.29 Moreover, in other
clinical trials of 5-HT3R antagonists, significant consti-
pation occurred in approximately 25% of patients,
leading to withdrawal of up to 10% of patients from
the treatment.53 Because constipation related adverse
events induced by 5-HT3R antagonists seem to reduce
compliance, we allowed our subjects to reduce their
dose to avoid adverse events such as constipation and
ischemic colitis. Our response rate to ramosetron was
about 62%and ismuchgreater compared to the previous
Japanese study,29 although their response might have
been weaker after accounting for placebo effects. More-
over, our higher responder rate might be due to the
improvement in compliance by allowing our subjects to
reduce their ramosetron dose. Indeed, baseline scores for
diarrhea tended to be higher in the responders than in
the non-responders and the frequency of reducing the
dose due to constipation was higher in the responders
than in the non-responders. These results suggest that
the ramosetron effects were stronger especially against
diarrhea symptoms in the responders compared to the
non-responders.
The major limitations of this study are possible
selection bias especially relating to the relatively small
number of cases. To avoid accounting for placebo
effects, a placebo-controlled study is always ideal.
However, the aim of this study was to identify
underlying genetic variants predictive of a clinical
response to ramosetron therapy. Although our results
cannot exclude the possibility that some responses
were due to a placebo effect, we wish to emphasize that
this is the first study to collectively examine various
SNPs in several IBS-related genes that can form the
basis for a placebo-controlled study. Ramosetron is
only approved for men in Japan, and alosetron is
indicated only for women with severe chronic D-IBS
in USA because of serious GI events, which are
sometimes fatal, including ischemic colitis and bowel
motor dysfunction. We strictly selected the patients
with IBS-D excluding mixed type to avoid adverse
events, and therefore the enrollment of sufficient
numbers of patients at a single center was considered
to be difficult. Therefore to demonstrate significant
prediction of symptom relief with ramosetron using
multiple genetic variables will require a large-scale
multicenter double-blind, placebo-controlled study.
Moreover, future investigations could employ a gen-
ome-wide screening approach that might reveal addi-
tional genetic variants that correlate with the effect of
a 5-HT3R antagonist in IBS-D patients.
In summary, the baseline diarrhea score, S100A10
expression levels and an increase in the frequency of
the TPH1 rs4537731 T/T, rs7130929 C/C and rs211105
T/T genotypes were significantly higher in the ramose-
© 2014 John Wiley & Sons Ltd88
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tron responder group than those in the non-responder
group. Increased S100A10 and TPH1mRNA expression
as well TPH1 promoter and intronic SNPs appear to
predict higher 5-HT signaling, and correlates not only
with diarrhea symptoms, but also with greater ramose-
tron effectiveness in IBS-D patients. The minor allele
for TPH1 rs211105 may possibly lead to prospective
identification of ramosetron non-responders.
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